Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lexaria Bioscience Corp.LEXX · Entity 7641 | Director | May 15, 2025 | May 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lexaria Bioscience Corp.
Report date May 15, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2030-05-15 | Direct | 63,000 |
Reported balance
After 2025-05-15 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-05-15 · Grant · Acquired 11,000 · Balance 63,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-04-26 | Direct | 1,500 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 1,500 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-06-08 | Direct | 6,500 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 6,500 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-09-01 | Direct | 8,400 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 8,400 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2027-03-08 | Direct | 11,800 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 11,800 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2027-10-12 | Direct | 30,000 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 30,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2028-07-25 | Direct | 35,000 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 35,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2029-04-26 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 40,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2029-07-26 | Direct | 52,000 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 52,000 |
| common sharesSEC Table I · non-derivative | Direct | 11,000 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 11,000 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EURASIA ENERGY LTD
Report date August 26, 2021 · Filed August 30, 2021
Section 16 reporting ended · disclosed 2021-08-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-08-26 transaction · row 1
1 source rowRow 1 · 2021-08-26 · Sale · Disposed 7,573,364 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 16, 2025 16:40 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 11,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001348362-25-000005 · primary_doc.xml · derivative · entry 10 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Shares · 11,000 shares Expires 2030-05-15 Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 11:25 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001348362-24-000002 · primary_doc.xml · derivative · entry 9 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Shares · 12,000 shares Expires 2029-07-26 Read SEC document |
| April 26, 2024 Filed May 10, 2024 17:11 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 5,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001855763-24-000008 · primary_doc.xml · derivative · entry 8 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 5,000 shares Expires 2029-04-26 Read SEC document |
| July 25, 2023 Filed Jul 25, 2023 14:35 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 5,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001855763-23-000005 · primary_doc.xml · derivative · entry 7 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 5,000 shares Expires 2028-07-25 Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 12:49 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 18,200 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001855763-22-000013 · primary_doc.xml · derivative · entry 6 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 18,200 shares Expires 2027-10-12 Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 17:18 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 3,400 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001855763-22-000001 · primary_doc.xml · derivative · entry 5 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Shares · 3,400 shares Expires 2027-03-08 Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 13:32 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 1,900 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001855763-21-000024 · primary_doc.xml · derivative · entry 4 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 Underlying: Common Shares · 1,900 shares Expires 2026-09-01 Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 19:36 UTC | EURASIA ENERGY LTD EUENF · Entity 135920 | SaleCommon Shares | 7,573,364 | $0.02 | $144,651.25 |
DisclosureSEC source: 0001312326-21-000001 · primary_doc.xml · nonDerivative · entry 1 Baxter Nicholas W · CIK 0001312326 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 11:32 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 5,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001855763-21-000012 · primary_doc.xml · derivative · entry 3 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Shares · 5,000 shares Expires 2026-06-08 Read SEC document |
| May 07, 2021 Filed Jun 9, 2021 11:23 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | OtherStock Options · Derivative | 5,000 | $0.00 Strike: $9.60 | $0.00 |
DisclosureSEC source: 0001855763-21-000011 · primary_doc.xml · derivative · entry 4 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Shares · 5,000 shares Expires 2025-04-23 F1 · kind: Cancellation of Options Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 16:52 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 1,500 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001855763-21-000004 · primary_doc.xml · derivative · entry 3 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Shares · 1,500 shares Expires 2026-04-26 Read SEC document |
| April 23, 2020 Filed Apr 23, 2020 14:00 UTC | Lexaria Bioscience Corp. LXRP · Entity 7641 | Grantstock options · Derivative | 150,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001312326-20-000002 · primary_doc.xml · derivative · entry 2 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: common shares · 150,000 shares Expires 2025-04-23 Read SEC document |
| March 23, 2020 Filed Mar 24, 2020 12:23 UTC | Lexaria Bioscience Corp. LXRP · Entity 7641 | Otherstock options · Derivative | 150,000 | $0.99 Strike: $0.99 | $148,500.00 |
DisclosureSEC source: 0001312326-20-000001 · primary_doc.xml · derivative · entry 3 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 150,000 shares Expires 2024-05-06 F1 · kind: Cancellation of options Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 11:52 UTC | Lexaria Bioscience Corp. LXRP · Entity 7641 | Exercise / conversionStock Options · Derivative | 110,000 | $0.10 Strike: $0.10 | $11,000.00 |
DisclosureSEC source: 0001312326-19-000003 · primary_doc.xml · derivative · entry 5 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 110,000 shares Expires 2019-12-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 11:52 UTC | Lexaria Bioscience Corp. LXRP · Entity 7641 | Exercise / conversioncommon shares | 110,000 | $0.10 | $11,000.00 |
DisclosureSEC source: 0001312326-19-000003 · primary_doc.xml · nonDerivative · entry 2 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2019 Filed Aug 7, 2019 13:34 UTC | Lexaria Bioscience Corp. LXRP · Entity 7641 | GrantStock Options · Derivative | 150,000 | $0.99 Strike: $0.99 | $148,500.00 |
DisclosureSEC source: 0001312326-19-000002 · primary_doc.xml · derivative · entry 1 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Shares · 150,000 shares Expires 2024-05-06 Read SEC document |
| April 05, 2019 Filed Apr 8, 2019 17:57 UTC | Lexaria Bioscience Corp. LXRP · Entity 7641 | OtherStock Options · Derivative | 50,000 | $1.53 Strike: $1.53 | $76,500.00 |
DisclosureSEC source: 0001348362-19-000004 · primary_doc.xml · derivative · entry 4 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 50,000 shares Expires 2023-05-31 F1 · kind: Cancellation of Options Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 15:06 UTC | Lexaria Bioscience Corp. LXRP · Entity 7641 | PurchaseOptions · Derivative | 50,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001312326-18-000002 · primary_doc.xml · derivative · entry 2 Baxter Nicholas W · CIK 0001312326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Lexaria Common Shares · 50,000 shares Expires 2023-05-31 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.